ImmunoPrecise Antibodies Ltd (IPA, Financial) is set to release its Q1 2025 earnings on Sep 16, 2024. The consensus estimate for Q1 2025 revenue is $4.97 million, and the earnings are expected to come in at -$0.10 per share. The full year 2025's revenue is expected to be $21.41 million and the earnings are expected to be -$0.25 per share. More detailed estimate data can be found on the Estimates page.
ImmunoPrecise Antibodies Ltd (IPA, Financial) Estimates Trends
Over the past 90 days, revenue estimates for ImmunoPrecise Antibodies Ltd (IPA) for the full year 2025 have decreased from $21.97 million to $21.41 million. The revenue estimate for 2026 has remained steady at $27 million. Earnings estimates for the full year 2025 have improved slightly from -$0.26 per share to -$0.25 per share, while the earnings estimate for 2026 has been revised downwards from -$0.12 per share to -$0.14 per share.
ImmunoPrecise Antibodies Ltd (IPA, Financial) Reported History
In the previous quarter of April 30, 2024, ImmunoPrecise Antibodies Ltd's (IPA) actual revenue was $4.76 million, which missed analysts' revenue expectations of $4.812 million by -1.1%. ImmunoPrecise Antibodies Ltd's (IPA) actual earnings were -$0.52 per share, which missed analysts' earnings expectations of -$0.085 per share by -507.06%. After releasing the results, ImmunoPrecise Antibodies Ltd (IPA) was down by -3.49% in one day.
ImmunoPrecise Antibodies Ltd (IPA, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 2 analysts, the average target price for ImmunoPrecise Antibodies Ltd (IPA) is $5.97 with a high estimate of $8.96 and a low estimate of $2.99. The average target implies an upside of 832.98% from the current price of $0.64.
Based on GuruFocus estimates, the estimated GF Value for ImmunoPrecise Antibodies Ltd (IPA, Financial) in one year is $5.02, suggesting an upside of 684.38% from the current price of $0.64.
Based on the consensus recommendation from 2 brokerage firms, ImmunoPrecise Antibodies Ltd's (IPA, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
